| Unsubscribe |
In 2022, I made a call that made people question my judgment.
I told my readers to buy Rolls-Royce. The stock was trading under $2.
Most people heard "Rolls-Royce" and pictured luxury cars for billionaires. A relic. A name from another era.
But that's not what I saw.
I saw a world-class aerospace company — one that builds the engines powering half the world's wide-body aircraft — hidden beneath a name the market had stopped taking seriously.
There was a massive disconnect between price and reality. And disconnects like that don't last forever.
The stock eventually climbed more than 1,100% over a 3–4-year period.
Over that time, some subscribers reported making $141,000. Others reported $272,000. One told us he'd made more than $1 million.
I believe the same kind of setup is unfolding right now — in a completely different sector. See what I'm looking at today.
I'm not bringing up Rolls-Royce to relive an old winner.
I'm bringing it up because the pattern I'm seeing today feels eerily familiar.
A misunderstood technology. A market that's barely paying attention. And a catalyst that could force investors to take a second look.
The technology is what I call the Energy Cube.
Here's what most people don't realize: there's a next-generation compact nuclear energy system — roughly the size of a shipping container — capable of powering up to 1,000 homes. No combustion. No emissions. It runs 24 hours a day regardless of whether the sun is shining or the wind is blowing. And it may be the single most viable answer to the biggest bottleneck in the AI buildout: the explosive demand for always-on, clean power that the current grid simply cannot meet.
Bill Gates has backed companies tied to it.
Jeff Bezos has backed companies tied to it.
Google and Microsoft are making billion-dollar commitments in the same direction.
Yet most investors still have no idea this technology — or the company behind it — even exists. Get the full story behind the Energy Cube.
That may change very soon.
The Nuclear Regulatory Commission is expected to issue a key approval decision as early as August — the first of its kind for this class of technology in over a decade. If that approval comes through, it would clear the single biggest regulatory hurdle standing between this company and full-scale commercial deployment. And it could force institutional capital off the sidelines overnight.
The market eventually figured out Rolls-Royce. By the time it did, the biggest gains were already behind the people who waited.
I believe the same window may be opening right now.
See Why I'm Making This Call Now
Yours in smart speculation,
Karim Rahemtulla
Co-Founder, Monument Traders Alliance
P.S. The NRC decision I'm watching is expected in August. If it plays out the way I anticipate, this stock may not stay under the radar much longer. I'd encourage you to watch my full presentation before then — while the opportunity is still ahead of the news cycle.
Atlassian’s AI Pivot Is Starting to Challenge Wall Street’s Bear Case
Written by Sam Quirke. Date Posted: 7/27/2026.
Key Points
- Atlassian has been pressured by concerns that AI coding tools could reduce demand for Jira, Confluence and other software-development products.
- The company is trying to turn that risk into an advantage by positioning Jira and Rovo as tools for coordinating AI-assisted software work.
- Atlassian’s valuation has reset sharply, but its next earnings report needs to show that AI momentum and cloud growth can continue.
- Special Report: SpaceX is offering you shares. Don't take them.
Few software names have been hit as hard by the market's artificial intelligence (AI) anxiety this year as Atlassian Corporation (NASDAQ: TEAM). The company behind popular workplace tools Jira and Confluence has seen its shares fall roughly 45% year to date, dragged down by fears that AI coding tools will make much of what it does redundant.
But that story is increasingly at odds with what the business is actually doing. Like many of its peers, Atlassian is not being disrupted. Instead, it has been quietly repositioning itself at the center of how AI is used inside software teams, and the stock has been grinding higher since April as a result.
Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid (Ad)
A small Colorado company has secured rights to technology that could prevent the U.S. public power grid from collapsing — and billionaire Sam Altman is now an investor.
This under-the-radar firm is drawing serious attention from those watching the energy infrastructure space closely.
Click here to learn this company's name for free todayWith the company due to report earnings in early August and several analysts calling for significant upside from current levels, Atlassian's setup ahead of the report looks more compelling than the bearish AI narrative suggests.
AI May Be Helping Atlassian More Than Hurting It
The single biggest fear hanging over Atlassian is that AI agents capable of writing code and resolving tickets will erode demand for its products. It's a reasonable worry on the surface, and it made sense earlier this year, but it is already starting to look outdated.
Rather than being replaced by AI, the company has been positioning Jira as the coordination layer within which AI agents operate. AI agents can handle plenty of individual tasks, but they can't replicate everything a full platform brings to the table, from managing complex workflows to coordinating large teams throughout a development lifecycle. Someone still has to orchestrate all those agents, and Atlassian wants to be where that happens.
The early evidence suggests that strategy is gaining traction, with adoption of the company's Rovo AI platform gathering pace throughout the year. Crucially, that adoption is showing up alongside durable, contractually backed growth in Atlassian's underlying business rather than replacing it. That is the opposite of what the disruption thesis would predict.
Atlassian's Valuation No Longer Looks Like the Problem
The valuation reset is another major part of the case. After a punishing, multimonth sell-off, Atlassian now trades at valuations far below where they were just last year.
On several measures, including price-to-sales and price-to-free-cash-flow, the stock sits well below its recent historical range. That decline has been driven largely by the shares falling more than 80% since their 2021 peak. For a company still reporting record revenue and accelerating growth in recent quarters, that's a significant disconnect. The market has effectively repriced Atlassian as though its growth days are behind it, while the underlying figures suggest the opposite.
The Recovery Is Starting to Look More Durable
The market has quietly started to change its mind. Atlassian bottomed at a multiyear low in April and has since climbed more than 50% from that level.
That recovery hasn't come out of nowhere. The company has beaten analyst expectations in its earnings reports along the way, helping rebuild the credibility that the AI panic had stripped away. A stock putting in a series of higher lows while consistently exceeding forecasts is usually telling you something. In this case, it suggests that investors have been accumulating Atlassian at a discount while the broader market has been writing it off.
That combination—an improving technical picture backed by real fundamental momentum—is exactly the kind of setup that tends to precede a sustained move rather than a short-lived bounce.
Earnings Will Decide Whether the Rebound Has Legs
This puts the pressure on Atlassian going into next month's report. The company has to prove that its AI momentum is translating into revenue capable of justifying the stock's continued recovery, while reassuring investors that the cost of building out all that AI capability isn't about to spiral out of control.
Atlassian currently carries a Moderate Buy consensus rating, with an average price target near $139, implying significant upside from recent trading levels. While several firms have reiterated bullish ratings recently, others are more cautious. Bank of America, for instance, holds only a Neutral rating on the stock. Tellingly, however, even its recently refreshed price target sits comfortably above where Atlassian's shares currently trade, underscoring how much bad news is already baked into the price.
That's ultimately what makes the risk-reward look so appealing here. With the stock trading below even the more cautious targets on Wall Street, the downside appears limited, while the upside could be considerable if the AI pivot continues to deliver. For investors willing to look past a narrative that the company itself keeps disproving, Atlassian heading into earnings looks like a rare chance to buy a quality business while it remains deeply out of favor.
Bearish Pressure Is Building Around These 3 Stocks
Written by Jessica Mitacek. Date Posted: 8/3/2026.
Key Points
- A growing wave of bearish bets against AI-linked and semiconductor stocks is starting to pay off after three years of record market highs.
- Short sellers have targeted Hims & Hers Health and QXO, betting against regulatory troubles, dilution risk, and mounting net losses at each company.
- KLA has instead suffered a steep valuation-driven decline of nearly 40% since June amid fears that chipmakers will curb AI-related capital spending.
- Special Report: SpaceX is offering you shares. Don't take them.
For the past three years, the market has seen a series of record highs as the AI trade pushed the major indices higher. But amid that exponential growth, bearish bets have begun to increase, and now they appear to be paying off.
The current sell-off has had an adverse and outsized impact on chipmakers and Magnificent Seven stocks. Tesla (NASDAQ: TSLA), for instance, is down around 30% year-to-date (YTD), including a decline of nearly 27% in July. Meanwhile, South Korean semiconductor manufacturer SK hynix (NASDAQ: SKHY) has slid about 14% since its July 10 Nasdaq listing.
Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid (Ad)
A small Colorado company has secured rights to technology that could prevent the U.S. public power grid from collapsing — and billionaire Sam Altman is now an investor.
This under-the-radar firm is drawing serious attention from those watching the energy infrastructure space closely.
Click here to learn this company's name for free todayHims & Hers Health (NYSE: HIMS) and QXO (NYSE: QXO) illustrate the short-selling side of that bearish shift, with both ranking among the market’s most heavily shorted stocks. KLA (NASDAQ: KLAC) represents a different setup: The semiconductor equipment maker has faced a sharp, valuation-driven sell-off amid concerns about chip-industry capital spending and the durability of AI demand.
Together, the three companies show how bearish pressure can build through very different channels—and why investors need to distinguish between a crowded short trade and a broader reset in expectations.
High-Beta Hims & Hers Health Has Become a Target for Short Sellers
Short sellers have made healthcare provider Hims & Hers Health one of the market’s most heavily shorted stocks.
Some 61.4 million shares were sold short, representing 30% of the company’s public float and approximately $2.29 billion, as of July 15.
On July 29, the Federal Trade Commission (FTC), Utah, and California sued Hims & Hers over alleged privacy, billing, and cancellation practices, adding a new legal and regulatory risk.
In May, the company announced a $350 million private offering of convertible senior notes due June 1, 2032. The offering stoked fears of shareholder dilution, although Hims & Hers entered into capped-call transactions intended to reduce potential dilution. Much of the offering is earmarked for the Eucalyptus acquisition, but more broadly, it supports the company’s long-term international expansion plan.
Hims & Hers missed analyst expectations for both revenue and earnings per share (EPS) in the first quarter. The company’s elevated customer acquisition costs have also increased the risk of margin compression, spooking some investors.
Over the past year, insider selling has dwarfed buying, totaling about $87 million compared with just $1.17 million.
But the company has benefited from several tailwinds, too.
From avoiding a lawsuit with Novo Nordisk (NYSE: NVO) and agreeing to distribute the Danish pharmaceutical company’s flagship GLP-1 drugs Ozempic and Wegovy, to the $1.15 billion acquisition of Australian telehealth platform Eucalyptus, the company has positioned itself to deliver long-term shareholder value.
The stock is up around 100% from its YTD low in late February.
For buy-and-hold investors who are focused on the bigger picture and able to stomach the stock’s 2.35 beta, institutional ownership remains strong, while HIMS’ financial health has been in TradeSmith’s Green Zone for more than four months. The average 12-month price target also suggests about 13% potential upside from current prices.
QXO’s Losses and Valuation Draw Heavy Short Interest
Unlike the other two stocks on this list, QXO (NYSE: QXO) is not the victim of its own success.
Shares are down nearly 31% YTD and nearly 94% from their five-year high in June 2024.
The company distributes and installs building products, serving an estimated $800 billion market.
Its operations include roofing, insulation, lumber, waterproofing products, and other construction materials.
QXO has become a target for short sellers largely because of a disconnect between its valuation and financial performance.
In the first quarter, the company’s net loss grew to $227 million, marking the fourth consecutive quarter in which it operated at a loss. On an annualized basis, QXO has averaged a net loss of more than $50 million over the past five years, with the company turning a profit in just one of those years: $28 million in 2024.
Current short interest stands at nearly 25% of the float, or about 106 million shares out of 725.3 million shares outstanding.
But a bottom may be in before short sellers can exit their positions. Short interest is down more than 35% month over month, and analysts’ average 12-month price target suggests as much as 120% potential upside. The stock has received a Moderate Buy rating.
KLA Gets Caught Up in the Semiconductor Sell-off
KLA fits squarely into the current AI sell-off. But its market capitalization of nearly $240 billion pales in comparison with that of the hyperscalers.
The company designs and manufactures equipment, software, and services used by chipmakers to analyze and control manufacturing processes, detect defects, measure critical dimensions, and improve yields across wafer fabrication, photomask, and packaging operations.
Over the past year, the stock is up nearly 107% following a remarkable streak of earnings beats.
But that hasn’t kept the company from being caught up in the rotation out of semiconductor names.
Since hitting its all-time high on June 30, KLAC is down nearly 40%. Unlike Hims & Hers and QXO, however, KLA’s bearish pressure has primarily manifested as a steep share-price decline rather than unusually elevated short interest.
Like its larger counterparts, KLA has suffered from overvaluation concerns and a subsequent exodus of investors hedging against a cyclical slowdown in semiconductor companies, fueled by perceptions of unsustainable AI spending. That capital spending is KLA’s lifeblood, and if spending is curtailed, it could adversely affect the company’s share price.
But KLA dominates its niche. The company holds between 50% and 60% of the wafer inspection market and between 40% and 50% of the metrology equipment market. Despite the sharp sell-off, institutional ownership remains robust at nearly 87%, with inflows of more than $495 million surpassing outflows of just over $70 million over the past year. While gains may slow, analysts see more than 22% potential upside over the next 12 months.
This email content is a paid sponsorship provided by Monument Traders Alliance, a third-party advertiser of Earnings360 and MarketBeat.
This ad is sent on behalf of The Oxford Club. 105 W Monument St, Baltimore, Maryland 21201. If you would like to optout from receiving offers from The Oxford Club please click here
If you need assistance with your subscription, feel free to email MarketBeat's U.S. based support team at contact@marketbeat.com.
If you no longer wish to receive email from Earnings360, you can unsubscribe.
© 2006-2026 MarketBeat Media, LLC. All rights protected.
345 N Reid Place, Sixth Floor, Sioux Falls, S.D. 57103. United States of America..
No comments:
Post a Comment